Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph early_phase_1
4
80%
Ph phase_1
1
20%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
4(80.0%)
Phase 1Safety & dosage
1(20.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Other(2)

Detailed Status

Recruiting3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 14 (80.0%)
Phase 11 (20.0%)

Trials by Status

unknown240%
recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_1

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT06464679
recruitingearly_phase_1

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

NCT06318533
recruitingearly_phase_1

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

NCT06469190
unknownearly_phase_1

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT05673447
unknownearly_phase_1

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03690310

Clinical Trials (5)

Showing 5 of 5 trials
NCT06464679Phase 1

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Recruiting
NCT06318533Early Phase 1

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Recruiting
NCT06469190Early Phase 1

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

Recruiting
NCT05673447Early Phase 1

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Unknown
NCT03690310Early Phase 1

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5